Application No. 10/582,174 Amendment dated November 5, 2010

Reply to Office Action of June 8, 2010

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A medicament-containing particle wherein an unpleasant taste of the

medicament is alleviated, which is obtainable by mixing and granulating a composition

consisting essentially of the following ingredients:

(1) the medicament with an unpleasant taste,

(2) methylcellulose, and

(3) mannitol,

wherein the amount of the methylcellulose is about 0.8 to about 10 parts by weight per 1 part by

weight of the medicament with an unpleasant taste, and the amount of the mannitol is about 0.3

to about 12 parts by weight per 1 part by weight of the methylcellulose, and said particle lacks a

coating.

2-3. (Cancelled)

4. (Original) The medicament-containing particle according to claim 1 wherein the amount of the

methylcellulose is about 0.8 to about 5 parts by weight per 1 part by weight of the medicament

with an unpleasant taste.

5. (Cancelled)

6. (Previously Presented) The medicament-containing particle according to claim 1 or 4 wherein

the amount of the mannitol is about 0.5 to about 12 parts by weight per 1 part by weight of the

methylcellulose.

7. (Previously Presented) The medicament-containing particle according to claim 1 or 4 wherein

the amount of the mannitol is about 0.7 to about 7.5 parts by weight per 1 part by weight of the

methylcellulose.

DRN/MHE/whg

Docket No.: 0020-5490PUS1

2

8. (Previously Presented) The medicament-containing particle according to claim 1 wherein the mannitol is D-mannitol.

- 9. (Previously Presented) The medicament-containing particle according to claim 1 wherein the medicament with an unpleasant taste is 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide or a pharmaceutically acceptable salt thereof.
- 10. (Previously Presented) The medicament-containing particle according to claim 1 which is obtainable by mixing and granulating a composition consisting essentially of the following ingredients:
- (1) (±)-4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide citrate dihydrate as a medicament,
- (2) methylcellulose, and
- (3) D-mannitol,

wherein the amount of the methylcellulose is about 0.8 to about 10 parts by weight per 1 part by weight of (±)-4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]-methyl]benzamide citrate, and

the amount of the D-mannitol is about 0.5 to about 12 parts by weight per 1 part by weight of the methylcellulose.

- 11. (Previously Presented) A solid preparation comprising the medicament-containing particle set forth in claim 1 and other pharmaceutically acceptable ingredients for pharmaceutical preparation.
- 12. (Cancelled)
- 13. (Previously Presented) The solid preparation according to claim 11 wherein the solid preparation is in the form of a tablet or a pill.

Docket No.: 0020-5490PUS1

14. (Previously Presented) The solid preparation according to claim 11 wherein the solid

preparation is in the form of a granule, a fine granule or a powder.

15. (Previously Presented) The solid preparation according to claim 11 which is an intrabuccally

rapidly disintegrating preparation.

16. (Original) The solid preparation according to claims 15 wherein the intrabuccally rapidly

disintegrating preparation is in the form of a tablet.

17. (Previously Presented) The solid preparation according to claim 15 wherein the intrabuccally

rapidly disintegrating preparation is in the form of a granule, a fine granule, or a powder.

18. (Previously Presented) The intrabuccally rapidly disintegrating preparation set forth in claim

15 which is characterized by the following properties:

(i) disintegrating within 40 seconds on a tongue of a healthy adult with his mouth closed

and without chewing,

(ii) dissolving at a substantial dissolution rate of 85% or more after 15 minutes according

to the dissolution test described in the Japanese Pharmacopoeia XIV [using Method 2 (50 rpm)

for tablets or Method 1 (50 rpm) for the form of a granule, a fine granule, or a powder, resolution

medium: 900 mL of water], and

(iii) not substantially producing an unpleasant taste on setting the preparation in buccal

cavity.

19. (Previously Presented) A composition for preparing the intrabuccally rapidly disintegrating

preparation set forth in claim 15, which comprises

(a) a medicament-containing particle wherein an unpleasant taste of the medicament is

alleviated, which is obtainable by mixing and granulating a composition consisting essentially of

the medicament with an unpleasant taste, methylcellulose, and mannitol;

(b) an excipient; and

DRN/MHE/wha

Docket No.: 0020-5490PUS1

4

lication No. 10/582,174 Docket No.: 0020-5490PUS1

(c) a disintegrator.

20. (Previously Presented) A process for preparing a medicament-containing particle wherein an

unpleasant taste of the medicament is alleviated, comprising mixing and granulating a

composition consisting essentially of the following ingredients, with water or a water containing

solvent: (1) the medicament with an unpleasant taste, (2) methylcellulose whose amount is about

0.8 to about 10 parts by weight per 1 part by weight of the medicament with an unpleasant taste

and (3) mannitol whose amount is about 0.3 to about 12 parts by weight per 1 part by weight of

the methylcellulose.

21. (Original) A commercial package which comprises the solid preparation set forth in claim 11

comprising 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-

morpholinyl]methyl]benzamide or a pharmaceutically acceptable salt thereof as a medicament

with an unpleasant taste; and a written matter as to the solid preparation,

including a description on the outside of the package or in the written matter inside the package

which intends that the solid preparation can/should be used for promoting gastrointestinal

motility, improving postgastrectomy condition, or preventing/treating gastroesophageal reflux

disease (GERD).

22. (Previously Presented) The medicament-containing particle according to claim 1 or 4

wherein the composition further consists of a binder.

23. (Previously Presented) The process according to claim 20 wherein the composition further

consists of a binder.

24. (Previously Presented) The solid preparation according to claim 11 wherein the medicament-

5

containing particle further consists of a binder.

DRN/MHE/whg

Application No. 10/582,174 Amendment dated November 5, 2010 Reply to Office Action of June 8, 2010

- 25. (Previously Presented) The medicament-containing particle according to claim 1 which consists of the following ingredients:
 - (1) a medicament with an unpleasant taste,
 - (2) methylcellulose, and
 - (3) mannitol.
- 26. (Previously Presented) The medicament-containing particle according to claim 1 which consists of the following ingredients:
 - (1) a medicament with an unpleasant taste,
 - (2) methylcellulose,
 - (3) mannitol, and
 - (4) a binder and/or fluidization agent.
- 27. (Currently Amended) The medicament-containing particle according to claim 1 which consists of the following ingredients:
 - (1) a medicament with an unpleasant taste,
 - (2) methylcellulose,
 - (3) mannitol, and
- (4) I to 4 ingredients selected from the group consisting of a binder, a fluidization agent, a corrigent and a disintegrant, wherein the corrigent is one or more selected from the group consisting of neotame, thaumatin, aspartame, stevia, saccharin sodium, and sodium glutamate.

Docket No.: 0020-5490PUS1